S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models.

Lauren R BeggAdrienne M OrriolsMarkella ZannikouChen YehPranathi VadlamaniDeepak KanojiaRosemary BolinSara F DunneSanjeev BalakrishnanRoman CamardaDiane RothNicolette A Zielinski-MoznyChristina YauAthanassios VassilopoulosTzu-Hsuan Huang Kwang-Youn A Kim Dai Horiuchi

Published in: Communications medicine (2024)

Our data propose S100A8/A9 as a potential predictive and pharmacodynamic biomarker in clinical trials evaluating combination therapy targeting PIM and immune checkpoints in TNBC. This work encourages the development of S100A8/A9-based liquid biopsy tests for treatment guidance.

Keyphrases

combination therapy
clinical trial
mouse model
electronic health record
cancer therapy
randomized controlled trial
tyrosine kinase
climate change
machine learning
open label
fine needle aspiration
smoking cessation
study protocol